KDC-MN-185 – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

SAM-e is the body’s principal methyl donor, used in countless biological reactions including neurotransmitter synthesis. As a supplement it has antidepressant effects with reasonable evidence and is used for liver disease and osteoarthritis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

Decades-old methyl donor with real but modest clinical evidence, largely mined-out research territory

SAM-e has been a fixture in the depression and liver-disease literature since Italian investigators began publishing on it in the 1970s. Fifty years of literature is the first signal: this isn’t a discovery, it’s established biochemistry. The mechanism is real. SAM-e is the universal methyl donor, participating in over 100 cellular transmethylation reactions including DNA methylation, neurotransmitter precursor steps, and phosphatidylcholine synthesis via the PEMT pathway. What we like is that this actually matters biologically. What we dont like is that “biologically important” and “interesting current research target” arent the same thing.

The clinical story is genuinely better than most compounds in this library. Several European regulatory agencies approved SAM-e as a prescription medicine for depression and osteoarthritis, and that’s translational signal most research compounds will never achieve. Meta-analyses, including the Papakostas group’s work and the AHRQ systematic review, report antidepressant effect sizes broadly comparable to SSRIs in small-N comparisons (SMD roughly 0.3 to 0.5). The OA data is similarly positive at modest scale. There’s also a hepatoprotective literature, particularly for alcohol-associated liver disease and NAFLD, where methionine cycle disruption is mechanistically coherent and the evidence is credible.

Here’s the problem: none of this is generating new questions. The depression literature effectively peaked in the late 1990s and early 2000s. Researchers cite those trials in background sections now, not as frontiers to build on. The mechanism is too diffuse to work as a specific probe; methylating everything across a hundred pathways isn’t the same as answering a targeted biological question. If you want to perturb DNA methylation specifically, DNMT inhibitors like 5-azacytidine or decitabine give precision that SAM-e can’t. If you’re working on one-carbon metabolism, SAM-e tends to be an output you measure, not the primary intervention you deploy.

The most live contemporary angle is in liver disease and, to a lesser extent, the aging/epigenetics interface. Groups studying MAT1A to MAT2A synthetase isoform switching in ALD and NAFLD, including work from Mato and colleagues at CIC bioGUNE on hepatic methionine cycle dysregulation, are doing genuinely interesting things with SAM-e as a metabolic variable. Thats the narrowest slice where we’d still look for new signal. But it’s a contracting frontier, not an expanding one.

Honestly, SAM-e scores like what it is: an endogenous metabolite with fifty years of evidence, a mechanism that’s well-understood and diffuse, and no category where it’s clearly best-in-class today. The clinical evidence is better than many compounds at this score level, which keeps it from the floor, but there’s little here to build a new program around. Solid reference material for background reading, not a primary target.

Novelty: 18
Mechanism promise: 30
In-category differentiation: 35
Evidence quality: 52
Translational signal: 58
Research bench value: 38

Rationale SAM-e is foundational endogenous biochemistry with a genuine multi-decade clinical literature in depression and liver disease, but the mechanism is too diffuse to serve as a specific research probe, the literature peaked in the early 2000s, and there is no category where it is clearly best-in-class today; the raw calculation lands just under the foundational-metabolite structural ceiling.

Endogenous methyl donor

S-adenosyl-L-methionine, the principal methyl donor for cellular methylation reactions, supplemented for depression, osteoarthritis, and liver disease.

Abstract

SAM-e (S-adenosyl-L-methionine; CAS 29908-03-0; molecular formula C15H22N6O5S; molecular weight 398.44) is an endogenous nucleotide-amino acid conjugate that serves as the principal methyl donor for hundreds of cellular methylation reactions, including DNA methylation, neurotransmitter synthesis, phospholipid synthesis, and detoxification. Synthesis from methionine + ATP is rate-limited; supplementation provides methyl donor capacity. The compound is approved as a medicine in some European countries for depression and osteoarthritis; sold as a dietary supplement in the United States. Clinical evidence in depression is moderate (effect sizes comparable to standard antidepressants in small trials). Doses are typically 400 to 1600 mg per day in divided administrations. Can precipitate mania in bipolar patients; should not be combined with MAOIs.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-185Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-185

SAM-e (S-Adenosyl-L-Methionine)

Abstract

Read the full monograph